Atty Dkt. No.: UCDV-286

USSN: 10/663,454

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 7-12, 16, 22-32, 34, and 37 without prejudice to renewal.

Please enter the amendments to claims 1, 3, 5, 6, 13, 18, 20, 21, and 39-43, as shown below.

- 1. (Currently amended) A non-human transgenic mammal comprising a transgene comprising a nucleotide sequence encoding a fatty acid desaturase, wherein said fatty acid desaturase-encoding nucleotide sequence is operably linked to a mammary gland-specific promoter, wherein the transgene is expressed in a mammary gland epithelial cell of said mammal, and wherein said mammal produces milk comprising a tissue of said mammal comprises a level of monounsaturated fatty acids (MUFA) that is at least 5% higher than the level of MUFA in the same tissue of milk produced by a non-transgenic mammal of the same species.
 - 2. (Canceled)
- 3. (Currently amended) The transgenic non-human animal mammal according to Claim 1, wherein said mammal is an ungulate.
 - 4. (Canceled)
- 5. (Currently amended) The transgenic non-human <u>mammal</u> animal according to Claim 1, wherein said transgene is chromosomally integrated.
- 6. (Currently amended) The transgenic non-human mammal according to Claim 1, wherein said transgene comprises a nucleotide sequence encoding fatty acid desaturase is a stearoyl-CoA desaturase operably linked to an animal tissue specific promoter.

7.-12. (Canceled)

Atty Dkt. No.: UCDV-286 USSN: 10/663,454

13. (Currently amended) A method for producing a non-human transgenic mammal of claim 1, said method comprising:

- (a) introducing a <u>fatty acid</u> desaturase transgene into a single-celled embryo, forming a genetically modified embryo, wherein said transgene comprises a nucleotide sequence encoding a fatty acid desaturase and wherein said fatty acid desaturase-encoding nucleotide sequence is operably linked to a mammary gland-specific promoter; and
- (b) transferring the genetically modified embryo into a recipient female of the same species as the embryo, wherein the genetically modified embryo develops into a transgenic mammal in the female.
- 14. (Previously presented) The method according to Claim 13, wherein said transgenic mammal is chosen from a mouse, a rat, a rabbit, a pig, a sheep, a goat, and a cow.
- 15. (Previously presented) The method according to Claim 13, wherein said transgene is expressed in mammary gland cells of said mammal.

16. (Canceled)

- 17. (Original) The method according to Claim 13, wherein the desaturase transgene is a stearoyl-CoA desaturase transgene.
- 18. (Currently amended) A method for producing a non-human transgenic mammal according to claim 1, said method comprising:
 - a) introducing a <u>fatty acid</u> desaturase transgene into a mammalian somatic cell, forming a genetically modified somatic cell comprising a genetically modified nucleus;
 - b) transferring the genetically modified nucleus from the genetically modified somatic cell into a single-celled embryo, generating a genetically modified single-celled embryo; and
 - c) transferring the genetically modified single-celled embryo into a recipient female of the same species as the embryo, wherein the genetically modified embryo develops into a transgenic mammal in the female.

Atty Dkt. No.: UCDV-286

USSN: 10/663,454

19. (Original) The method of claim 18, wherein the desaturase transgene is a stearoyl CoA desaturase transgene.

- 20. (Currently amended) A method of producing a food product, said method comprising harvesting a food product from a non-human transgenic mammal of Claim 1, wherein said food product is milk.
- 21. (Currently amended) A method of producing a food product, the method comprising processing a food product harvested from a non-human transgenic mammal of Claim 1, wherein said food product is milk.

22.-32. (Canceled)

33. (Previously presented) The transgenic mammal of claim 1, wherein said mammal is a female that produces milk comprising a level of polyunsaturated fatty acids (PUFA) that is at least 5% higher than the level of PUFA in milk produced by a non-transgenic mammal of the same species.

34. (Canceled)

- 35. (Previously presented) The transgenic mammal of claim 1, wherein said mammal is a female that produces milk comprising a level of saturated fatty acids (SFA) that is at least 5% lower than the level of SFA in milk produced by a non-transgenic mammal of the same species.
- 36. (Previously presented) The transgenic mammal of claim 1, wherein said mammal is chosen from a goat, a cow, and a sheep.

37. (Canceled)

38. (Previously presented) The transgenic mammal of claim 1, wherein said mammal is a female that produces milk comprising a level of conjugated linoleic acid (CLA) that is at

Atty Dkt. No.: UCDV-286

USSN: 10/663,454

least 5% higher than the level of CLA in milk produced by a non-transgenic mammal of the same species.

- 39. (Currently amended) The transgenic mammal of claim $\underline{1}$ [[7]], wherein the mammary gland-specific promoter is a β -lactoglobulin promoter.
- 40. (Currently amended) The transgenic mammal of claim $\underline{1}$ [[7]], wherein the mammary gland-specific promoter is a β -casein promoter.
- 41. (Currently amended) The transgenic mammal of claim $\underline{1}$ [[7]], wherein the mammary gland-specific promoter is an α S1-casein promoter.
- 42. (Currently amended) The transgenic mammal of claim $\underline{1}$ [[7]], wherein the mammary gland-specific promoter is an α S2-casein promoter.
- 43. (Currently amended) The transgenic mammal of claim 1 [[7]], wherein the mammary gland-specific promoter is a whey acid protein promoter.